Answers are grounded in this paper and cite their sources.
The purpose of the this study was to defined protective effects of silymarin on the experimental colitis induced by intra-colonic application of 2,4,6-trinitrobenzene sulfonic acid (TNBS). The twenty eight Sprague-Dawley rats were randomly seperated into four groups, each group containing seven rats represent as follows: group 1 determined as control; group 2 determined as colitis-untreated; group 3 determined as colitis rats administered silymarin (50 mg/kg) and group 4 determined as colitis rats administered silymarin (100 mg/kg). Doses of 50 mg/kg and 100 mg/kg silymarin decreased tissue levels of malondialdehyde (MDA), cathepsin L and cathepsin B and activity of myleperoxidase (MPO) enzyme with respect to the colitis group (p<0.05). Based on the results of the study, it can be said that silymarin can be used as an effective treatment agent in inflammatory bowel diseases.
No takes yet. Share an insight, caveat, or question.
Bayramoğlu et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: